

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No. 01-270)

In re Application of:		ECHOO 083 E		
	Pacciarini et al.)))) Group Art Unit: 1623		
Serial No.:	09/786,998) Group Art Offic. 1023		
Filing Date	:: June 14, 2001	Examiner: Howard V. Owens Jr.		
For: Use of Methoxymorpholino Doxorubicin for the Treatment of a Liver Tumor)))		

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

In regard to the above identified application:

- 1. We are transmitting herewith the attached:
 - a. Information Disclosure Statement including 3 cited references;
 - b. PTO Form 1449; and
 - Return Receipt Postcard
- 2. With respect to additional fees:
 - X No additional fee is required.
- 3. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.
- 3. CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1 hereinabove, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 30th day of June, 2003.

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Dated: June 30, 2003

Stephen H. Docter Reg. No. 44,659



UNITED STATES PATENT AND TRADEMARK OFFICE (Case No. 01-270)

In re Application of:)	TECH OR EIVEL
	Pacciarini et al.)	Group Art Unit: 1623
Serial No.:	09/786,998)	Group Art Offit: 1023
Filing Date:	June 14, 2001)	Examiner: Howard V. Owens Jr.
Doxe	Use of Methoxymorpholino Doxorubicin for the Treatment of a Liver Tumor		

PATENT

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to the duty of disclosure provided by 35 C.F.R. § 1.56 and §§ 1.97-98, the applicants wish to make the following references of record in the above-identified application. Copies of the references are enclosed. Copies are also listed in the PTO-1449 form enclosed herewith. It is requested that the documents be given careful consideration and that they be cited of record in the prosecution history of the present application so that they will appear on the face of the patent issuing from the present application.

Portions of the references may be material to the examination of the pending claims, however no such admission is intended. 37 C.F.R. 1.97 (h). The references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the

references. This Statement is not a representation that the cited references have effective

dates early enough to be "prior art" within the meaning of 35 U.S.C. sections 102 or 103.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)

The undersigned hereby certifies that each item of information cited in the present

Information Disclosure Statement was cited in Search Report from the counterpart

Russian no more than three months prior to the filing of the present Information

Disclosure Statement.

CITED REFERENCES

Other Documents

1. V.A. Gorbunova, Intrahepatic Arterial Infusion Chemotherapy for Primary and

Metastatic Cancer of the Liver.

2. Bioorganicheskaya Khimiya (Bioorganic Chemistry), E.N. Olsufjeva, Volume 18,

No. 2, 1992.

3. RU 2,065,307, Specification

Respectfully submitted,

McDonnell Boehnen Hulbert & Berghoff

Date: June 30, 2003

Stephen H. Docter

Registration No. 44,659

2